National Heart, Lung, and Blood Institute
NHLBI Early Phase Clinical Trials for Therapeutics and Diagnostics for HLBS Disorders (R33)
Deadline
January 7, 2027
Eligibility
United States, Foreign components allowed
Funding Amount
Unlock to view
Grant Overview
NHLBI Early Phase Clinical Trials for Therapeutics and Diagnostics for HLBS Disorders (R33) is a research funding opportunity offered by National Heart, Lung, and Blood Institute covering areas such as Clinical Trials, Heart, Lung, Blood, Sleep for applicants in United States, Foreign components allowed. The application deadline is January 7, 2027.
Researchers, universities, institutions and eligible organizations should review the funder requirements, geographic eligibility, research focus and deadline before preparing an application.
Focus Areas
Geographic Eligibility
- •United States
- •Foreign components allowed
Before You Apply
Confirm the final deadline, applicant requirements, funding conditions and submission instructions on the official funder website before submitting an application.